30
CARDIOVASCULAR
hamburger

With a commitment to advancing innovative technology to ensure people living with structural heart diseases have safe and effective treatment options, Abbott was the first to develop minimally invasive transcatheter treatment options for patients with mitral regurgitation (MR) and tricuspid regurgitation (TR), and reimagined the minimally invasive treatment of aortic stenosis.

MitraClip™ Therapy

MitraClip™ Transcatheter Mitral Valve repair (TMVr) procedure is a minimally invasive treatment option for select patients with primary or secondary MR. The first TMVr therapy recommended by AHA/ACC and ESC/EACTS Guidelines, MitraClip™ therapy makes intervention possible for more patients with MR.1,2 MitraClip TMVr procedure is a well-established therapy with a growing body of clinical and real-world experience.

Portico™ with FlexNav™ TAVI System

Portico™ with FlexNav™ Transcatheter Aortic Valve Implantation (TAVI) System offers patients with aortic valve stenosis a minimally invasive treatment option. The Portico™ valve is fully resheathable, repositionable, and retrievable, while the FlexNav™ delivery system offers remarkable flexibility and exceptionally smooth tracking to treat every TAVI case.

Tendyne™ TMVI System

Tendyne™ Transcatheter Mitral Valve Implantation (TMVI) System is first-in-class technology that offers select patients with MR, who are at high risk for surgery, a minimally invasive option for mitral valve replacement. Tendyne TMVI system provides symptom relief and quality of life improvement by safely and effectively reducing MR.

TriClip™ Tricuspid Valve Repair System

The TriClip™ Tricuspid Valve Repair System offers transcatheter tricuspid valve repair as a non-surgical, alternative treatment for select patients with tricuspid regurgitation (TR). TriClip Therapy uses the same technology as Abbott's clip-based technology in transcatheter mitral repair, with a delivery system uniquely designed for the right heart and tricuspid valve.3

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

References

  1. Otto C, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. Dec 17, 2020. Epublished DOI: 10.1016/j.jacc.2020.11.018.
  2. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(21):2739-2791.
  3. Data on file at Abbott.

MAT-2011954 v1.0 | Item approved for Global OUS use only.

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

True
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.